^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Thymus Cancer

    Related cancers:
    1m
    Cytokine Profiles in Myasthenia Gravis Subgroups and the Lack of Any Effect of Immunosuppression. (PubMed, Muscle Nerve)
    The findings reveal heterogeneous cytokine signatures among diverse MG subgroups, separating EOMG and MuSK-MG from TAMG and LOMG with some similarities and highlighting the impact of age and thymoma presence on immune responses. This assessment of disease subgroups has provided a broader understanding of the cytokines in MG.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL17A (Interleukin 17A) • IL13 (Interleukin 13) • IL21 (Interleukin 21) • IL4 (Interleukin 4)
    1m
    IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, Hospices Civils de Lyon | Recruiting --> Active, not recruiting | N=154 --> 27
    Enrollment closed • Enrollment change
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)
    1m
    A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=56, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2027 --> Mar 2028 | Trial primary completion date: Jun 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Bavencio (avelumab)
    2ms
    Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors. (PubMed, Cancer Res Commun)
    This first-in-human study demonstrates that IT or IV VV1 administration had an acceptable safety profile as monotherapy and IV in combination with avelumab. There is preliminary antitumor activity. IT VV1 plus cemiplimab is now showing promise in the neoadjuvant setting.
    P1 data • Journal • First-in-human
    |
    IFNB1 (Interferon Beta 1)
    |
    Bavencio (avelumab) • Libtayo (cemiplimab-rwlc)
    2ms
    Metaplastic Thymoma Underwent Open Thymectomy: A Rare Case Report of Biphasic Thymic Tumor. (PubMed, Case Rep Oncol)
    This case highlights the importance of integrating clinical, radiological, and histopathological findings for the accurate diagnosis of metaplastic thymoma. Complete surgical resection remains the treatment of choice and is associated with excellent long-term outcomes.
    Journal
    |
    YAP1 (Yes associated protein 1) • VIM (Vimentin) • TP63 (Tumor protein 63) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
    2ms
    Elevated serum Cyfra 21-1 levels predict poor prognosis in thymic tumors: a retrospective single-center study. (PubMed, J Thorac Dis)
    Cyfra 21-1 demonstrates potential as a valuable serum biomarker for both the diagnosis and prognosis of thymic tumors. Particular attention should be directed toward the diagnosis, treatment strategy, and postoperative surveillance of patients presenting with elevated Cyfra 21-1 levels.
    Retrospective data • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated) • KRT19 (Keratin 19)
    2ms
    The glutathione transferase omega 1-1 GSTO1*A140D polymorphism is associated with unfavourable prognosis in patients with thymoma and myasthenia gravis. (PubMed, Adv Med Sci)
    GSTO1*A140D polymorphism deserves to be further explored as a possible risk factor associated with a worse PFS in thymoma. Specific targets of GSTO1-1 in thymomas need to be determined.
    Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    HRAS mutation
    2ms
    Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors. (PubMed, NPJ Precis Oncol)
    ICIs demonstrated preliminary activity in thymic tumors but were associated with substantial toxicity, especially in thymoma. Biomarker-driven patient selection and vigilant irAE monitoring are needed.
    Journal • Adverse events • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    TP53 mutation
    2ms
    Zingerone Inhibits ox-LDL-Induced Human Coronary Artery Endothelial Cells Senescence and Apoptosis in Association With Downregulation of HSP90AB1 in Coronary Artery Atherosclerotic Heart Disease. (PubMed, J Biochem Mol Toxicol)
    Zin suppresses inflammation, senescence, and apoptosis of oxidized low-density lipoprotein-induced primary human coronary artery endothelial cells in a manner associated with HSP90AB1 silencing. These findings provide a foundation for the further development of Zin-based treatment strategies for CHD.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • TLR4 (Toll Like Receptor 4) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
    2ms
    Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors. (PubMed, JCO Precis Oncol)
    Integrated profiling of TETs reveals distinct genomic, transcriptomic, and immune features across subtypes of TETs and identifies potentially actionable therapeutic targets that may inform future treatment strategies.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • MTAP (Methylthioadenosine Phosphorylase) • MSLN (Mesothelin) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • TP53 mutation • TMB-H • MSI-H/dMMR • PD-L1 overexpression • HER-2 overexpression • EGFR expression • TMB-L • CDKN2A deletion
    |
    MI Tumor Seek™
    2ms
    Case Report: Anti-LGI1 encephalitis during FcRn inhibition with efgartigimod for myasthenia gravis: implications for the limitations of IgG recycling blockade. (PubMed, Front Immunol)
    High-dose intravenous methylprednisolone therapy resulted in marked clinical improvement. The absence of intrathecal IgG synthesis raises the possibility that pathogenic antibodies were predominantly derived from the peripheral compartment. These findings underscore the pharmacodynamic limitations of FcRn inhibition, particularly in the setting of thymoma-associated immune dysregulation.
    Journal
    |
    TTN (Titin)
    |
    methylprednisolone sodium succinate